Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Nutex Health (NUTX) EBITDA Margin (2017 - 2026)

Nutex Health (NUTX) has disclosed EBITDA Margin for 17 consecutive years, with 37.54% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 55.0% year-over-year to 37.54%; the TTM value through Mar 2026 reached 31.39%, down 222.0%, while the annual FY2025 figure was 31.49%, 426.0% up from the prior year.
  • EBITDA Margin hit 37.54% in Q1 2026 for Nutex Health, up from 20.38% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 48.68% in Q3 2025 and bottomed at 1509.7% in Q3 2022.
  • Average EBITDA Margin over 5 years is 77.0%, with a median of 6.96% recorded in 2024.
  • Year-over-year, EBITDA Margin plummeted -157282bps in 2022 and then surged 150839bps in 2023.
  • Nutex Health's EBITDA Margin stood at 10.76% in 2022, then plummeted by -249bps to 37.53% in 2023, then soared by 218bps to 44.33% in 2024, then tumbled by -54bps to 20.38% in 2025, then soared by 84bps to 37.54% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 37.54%, 20.38%, and 48.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.